companiesCompany
Bicycle Therapeutics
Inventor of bicyclic peptide drug conjugates; its lead Nectin-4 conjugate was deprioritised in 2026 after regulatory feedback.
Zelenectide pevedotin (BT8009) and BT5528 (EphA2); Bicycle radio-conjugates; partnerships with Bayer and Novartis on radiopharmaceuticals.